Intelligence and adaptive function in children diagnosed with brain tumour during infancy.

Department of Psychology, Murdoch Childrens' Research Institute, Royal Children's Hospital, Melbourne, Vic, Australia.
Journal of Neuro-Oncology (Impact Factor: 2.79). 01/2007; 80(3):295-303. DOI: 10.1007/s11060-006-9187-0
Source: PubMed

ABSTRACT Late effects of treatment in children diagnosed and treated for brain tumours in infancy is a major concern. Assessment of infants presenting with brain tumours is difficult and there is little information available regarding the development of infants prior to treatment and hence the impact of the tumour itself on developmental outcomes.
To describe the development of children diagnosed with brain tumours in infancy and to document their cognitive and adaptive function at school entry.
Infants were psychologically evaluated at the time of diagnosis of a brain tumour and during their fifth or sixth year in preparation for school entry.
Children diagnosed with brain tumours in infancy display developmental delays in a number of areas of adaptive function. By the time these children are school age they display further compromise in cognitive and academic skills and adaptive behaviour. Higher levels of deficit at follow-up were associated with tumour location in the supratentorium, younger age at diagnosis and longer time since diagnosis. The effect of radiotherapy could not be determined because of differing degrees of developmental compromise in the treatment groups at baseline.
Brain tumours in infancy confer a risk of poor developmental progress at the time of diagnosis. These children display additional compromise of development by the time they reach school age. Research protocols evaluating the impact of treatment in infants diagnosed with brain tumours need to take account of the developmental status of the child at diagnosis.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study investigated the relationship between posterior fossa tumors (astrocytoma and medulloblastoma) and their respective treatments and cognitive performance in Brazilian children by measuring Intelligence Quotient (IQ). Twenty children were enrolled in the study, of whom 13 were diagnosed with astrocytoma (average age at evaluation, 10.2 years; eight girls and five boys) and seven were diagnosed with medulloblastoma (average age at evaluation, 9.2 years; five girls and two boys). The first subgroup underwent exclusively tumor resection surgery, and the second subgroup underwent surgery, chemotherapy (Vincristine, Cisplatine, and Carmustine), and radiotherapy (total dose, 54 Gy). The inclusion criteria for the clinical group were normal social and emotional behavior before the diagnosis and motor and visual performance not excessively deteriorated after surgery. All participants were submitted to the Wechsler Intelligence Scale for Children - third version, and their scores were related to standard norms established for Brazilian children and compared with regard to the diagnosis subgroups and treatment modalities. Statistically significant differences were identified between the two diagnosis subgroups in Performance IQ and Processing Speed scores. The medulloblastoma subgroup presented poorer performance in all domains compared with the astrocytoma subgroup. Time interval between diagnosis and neuropsychological evaluation also had a significant effect on Processing Speed and Freedom from Distractibility in the medulloblastoma subgroup. These results provide empirical evidence of a possible significant effect of radiotherapy exposure on processing speed and global intellectual capacity.
    Psychology and Neuroscience 12/2010; 3(2):183-187.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resumen Los supervivientes de tumores cerebrales y leucemia sufren défi cit persistentes en una am- plia gama de funciones neuropsicológicas: aten- ción, velocidad de procesamiento, memoria, capacidad visoespacial y funciones ejecutivas. El propósito de este artículo es proporcio- nar información acerca de los procedimientos de evaluación y las técnicas que se utilizan en la actualidad para la evaluación de las secuelas neurocognitivas. El método más común que se utiliza para medir el défi cit cognitivo son las escalas de inteligencia (IQ tests), y entre ellas las más utilizadas, las escalas de Weschler. El uso de las nuevas escalas de Wechsler, WAIS-IV, WISC-IV y WPPSI-III puede interferir en la evaluación neuropsicológica de diferen- tes maneras. El efecto Flynn puede producir un aumento en el porcentaje de niños que se- rán clasifi cados como discapacitados, y esta discapacidad podría atribuirse a efectos del tratamiento. Ni siquiera existe una conexión exacta entre los antiguos del CIV y CIM y los índices actuales CV y RP, por lo tanto no es posible aplicar al WISC-IV en su totalidad los conocimientos adquiridos sobre los défi cits neurocognitivos con el uso del WISC-R. Es necesario el desarrollo de procedimien- tos de evaluación más fi ables y precisos que nos permitan conocer con más exactitud los décifi ts funcionales para contribuir al desarrollo de tra- tamientos menos tóxicos así como para diseñar programas de intervención más efi caces. Abstract Brain tumors and leukemia survivors frequently suffer severe and persistent defi cits in a wide range of neuropsychological functions such as attention, processing speed, memory, visuospatial skills and executive functions. The purpose of this article is to provide a better understanding about the current assessment procedures and techniques used to evaluate the neurocognitive sequelae. The most common method used to assess cognitive defi cits has been IQ tests being the Wechsler scales the most widely used. The use of the latest Wechsler scales WAIS- IV, WISC-IV and WPPSI-III might interfere on the neuropsychological assessment in many ways. The Flynn effect will result in a higher frequency of childrens being considered as impaired and their impairments will appear as if it was due to a treatment effect. It doesnt even exist an exact connection between the old VIQ and PIQ and the actual VC and PR indexes, therefore it isnt possible to apply completely to the WISC-IV the knowledge acquired on neurocognitive functions with the use of WISC-R. More accurate and reliable assessment is needed to know with more precision the functional defi cits in order to develop future less toxic treatments as well as more effective intervention programs.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adaptive functioning is not often examined in childhood brain tumor (BT) survivors, with the few existing investigations relying on examiner interviews. Parent questionnaires may provide similar information with decreased burden. The purpose of this study was: (1) to examine adaptive behaviors in BT survivors relative to healthy peer and cancer survivor groups, and (2) to explore the validity of a parent questionnaire in relation to an examiner administered interview. Participants (age 13.11 ± 2.98 years) were BT survivors treated with conformal radiation therapy (n = 50), healthy siblings of BT survivors (n = 39) and solid tumor (ST) survivors who did not receive CNS-directed therapy (n = 40). Parents completed the Adaptive Behavior Assessment System-2nd Edition (ABAS-II). For a subset of the BT cohort (n = 32), examiners interviewed the parents using the Vineland Adaptive Behavior Scales (VABS) within 12 months. Groups differed significantly on each of the ABAS-II indices and the general adaptive composite, with the BT group scoring lower than the sibling and ST groups across indices. Executive functioning, but not IQ, was associated with adaptive skills; no clear pattern of clinical and demographic predictors was established. VABS scores were correlated with ABAS-II scores on nearly all indices. BT survivors showed significantly lower adaptive functioning when compared to healthy and cancer controls. The ABAS-II proved sensitive to these behavioral limitations and was consistent with scores on the VABS. The use of a parent questionnaire to assess adaptive functioning enhances survivorship investigations by increasing flexibility of assessment and decreasing examiner burden.
    Journal of Neuro-Oncology 03/2014; · 3.12 Impact Factor


Available from
Oct 16, 2014